Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 8,129 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola sold 8,129 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total transaction of $46,497.88. Following the completion of the transaction, the chief financial officer now directly owns 83,811 shares of the company’s stock, valued at approximately $479,398.92. The trade was a 8.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Terns Pharmaceuticals Trading Down 0.7 %

NASDAQ TERN opened at $5.71 on Tuesday. Terns Pharmaceuticals, Inc. has a 12 month low of $4.32 and a 12 month high of $11.40. The stock’s fifty day moving average price is $6.35 and its 200-day moving average price is $7.41. The stock has a market cap of $485.00 million, a P/E ratio of -4.84 and a beta of -0.31.

Terns Pharmaceuticals (NASDAQ:TERN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. As a group, analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

TERN has been the topic of a number of research analyst reports. HC Wainwright reiterated a “neutral” rating and set a $7.50 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $26.00 price target (up from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday, September 16th. JMP Securities reissued a “market outperform” rating and set a $20.00 price objective on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th. Finally, Oppenheimer upped their target price on shares of Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 4th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.30.

Institutional Investors Weigh In On Terns Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Terns Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 154,714 shares of the company’s stock valued at $1,290,000 after acquiring an additional 1,994 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Terns Pharmaceuticals by 26.0% during the third quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company’s stock valued at $111,000 after purchasing an additional 2,751 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Terns Pharmaceuticals by 28.7% during the second quarter. The Manufacturers Life Insurance Company now owns 22,645 shares of the company’s stock valued at $154,000 after buying an additional 5,049 shares during the last quarter. Creative Planning increased its holdings in Terns Pharmaceuticals by 27.2% in the 3rd quarter. Creative Planning now owns 25,310 shares of the company’s stock worth $211,000 after buying an additional 5,409 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in Terns Pharmaceuticals in the 3rd quarter worth about $48,000. Institutional investors own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.